Novartis first in class siRNAtherapy, Leqvio gets US FDA approval to lower cholesterol and keep it low with two doses a year

Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.